Pancras CW Hogendoorn
Pancras CW Hogendoorn
Professor of Pathology, Leiden University Medical Center
Email verificata su
Citata da
Citata da
WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol. 5
C Fletcher, JA Bridge, PCW Hogendoorn, F Mertens
World Health Organization, 2013
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ...
The Lancet 364 (9440), 1127-1134, 2004
Pathology and genetics of tumours of soft tissue and bone
CDM Fletcher, KK Unni, F Mertens
Iarc, 2002
Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
JY Blay, S Bonvalot, P Casali, H Choi, M Debiec-Richter, AP Dei Tos, ...
Annals of Oncology 16 (4), 566-578, 2005
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
MF Amary, K Bacsi, F Maggiani, S Damato, D Halai, F Berisha, R Pollock, ...
The Journal of pathology 224 (3), 334-343, 2011
Sarcoma derived from cultured mesenchymal stem cells
J Tolar, AJ Nauta, MJ Osborn, A Panoskaltsis Mortari, RT McElmurry, ...
Stem cells 25 (2), 371-379, 2007
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...
The lancet oncology 15 (4), 415-423, 2014
The clinical approach towards chondrosarcoma
H Gelderblom, PCW Hogendoorn, SD Dijkstra, CS Van Rijswijk, AD Krol, ...
The oncologist 13 (3), 320-329, 2008
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ...
Cancer research 69 (13), 5383-5391, 2009
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are …
J Verweij, A van Oosterom, JY Blay, I Judson, S Rodenhuis, ...
European journal of cancer 39 (14), 2006-2011, 2003
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
JK Anninga, H Gelderblom, M Fiocco, JR Kroep, AHM Taminiau, ...
European journal of cancer 47 (16), 2431-2445, 2011
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
PJ Woll, P Reichardt, A Le Cesne, S Bonvalot, A Azzarelli, HJ Hoekstra, ...
The lancet oncology 13 (10), 1045-1054, 2012
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study
WG Goettsch, SD Bos, N Breekveldt-Postma, M Casparie, RMC Herings, ...
European journal of cancer 41 (18), 2868-2872, 2005
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma …
IJ Lewis, MA Nooij, J Whelan, MR Sydes, R Grimer, PCW Hogendoorn, ...
Journal of the National Cancer Institute 99 (2), 112-128, 2007
The histopathological differential diagnosis of gastrointestinal stromal tumours
JFG van Roggen, MLF Van Velthuysen, PCW Hogendoorn
Journal of clinical pathology 54 (2), 96-102, 2001
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label …
NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ...
The Lancet Oncology 17 (10), 1396-1408, 2016
Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating AgentsImpact of …
EP Buddingh, ML Kuijjer, RAJ Duim, H Bürger, K Agelopoulos, ...
Clinical Cancer Research 17 (8), 2110-2119, 2011
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and …
M Van Glabbeke, J Verweij, PG Casali, A Le Cesne, P Hohenberger, ...
Journal of Clinical Oncology 23 (24), 5795-5804, 2005
Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good …
SS Bielack, S Smeland, JS Whelan, N Marina, G Jovic, JM Hook, ...
Journal of Clinical Oncology 33 (20), 2279, 2015
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2
AB Mohseny, K Szuhai, S Romeo, EP Buddingh, I Briaire‐de Bruijn, ...
The Journal of Pathology: A Journal of the Pathological Society of Great …, 2009
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20